Back to search

Japan· JP-2122001X1010

キニジン硫酸塩水和物

A quinidine product containing キニジン硫酸塩水和物, registered in Japan, on the national reimbursement list. The same ATC class is registered in 6 of our 19 countries.

On Japan’s NHI price listATC C01BA01

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedキニジン硫酸塩水和物ATCC01BA01REGISTER NO.JP-2122001X1010PACKS LISTED0CHECKEDSeptember 25, 2026

Where it is registered

Quinidine is registered in 6 of 19 countries.

Countries holding a registration under ATC C01BA01 (quinidine), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 3 of them publish a price we can compare per daily dose

Quinidine · ATC C01BA01

6 / 19 countries

  • Finlandprice
  • Japan
  • Netherlands
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
キニジン硫酸塩水和物
Manufacturer
—
Country
Japan (JP)
ATC code
C01BA01
ATC class
Quinidine
Defined daily dose
1.2 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

491 interactions on record for quinidine.

Graded by severity as the source publishes them — 135 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Quinidine · interactions on record

491 records

  • 135 severe
  • 198 moderate
  • 8 minor
  • 108 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe

42 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Quinidine in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All quinidine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Hungary · Chinidin-Wagner
  • Netherlands · Kinidinesulfaat Teva
  • Romania · Chinidina

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a7efc82b-1e96-46a9-8a03-e90c86ba4466
GET /v1/drugs/a7efc82b-1e96-46a9-8a03-e90c86ba4466?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "1g",
  "marks": "局",
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2122001X1010",
  "category": "内用薬",
  "price_yen": null,
  "generic_name": "キニジン硫酸塩水和物",
  "product_name_jp": null,
  "therapeutic_class": "2122",
  "transitional_expiry": null
}

See everything about quinidine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.